How We Research and Fact-Check
Peptide News Digest is published by Longevity Insights LLC. This page explains where our facts come from, how we check them before publication, how we describe the strength of the evidence behind them, and how we correct mistakes when we make them.
Where our facts come from
We build every story and guide on primary records whenever they exist. For regulatory news, that means FDA and European Medicines Agency announcements, drug labels on DailyMed, the Federal Register, and trial registrations on ClinicalTrials.gov. For research, it means the published paper or its official abstract, matched to its PubMed, PMC, or DOI record. For company news, it means press releases and SEC filings, and we credit sales forecasts and other projections to the company that made them. For prices, it means manufacturer price pages, pharmacy and discount-card listings, and government data such as NADAC, a federal survey of what retail pharmacies pay for drugs. News coverage helps us find stories, and we cite it when it is the best available source, saying so in the text.
How we check a claim
Before a number appears on the site, we open the source and confirm that it says what we report. For a research finding, we check who was studied, how many people took part, the dose, what was measured, when it was measured, and what the drug was compared with. We keep a percentage change separate from a change in percentage points, and a relative reduction in risk separate from an absolute one, because mixing them can make a result look larger or smaller than it is. We check event dates against the official record rather than the date a news story ran. If we cannot confirm a detail from a reliable source, we leave it out.
How we describe evidence
We label each result by the kind of study behind it. Findings from animals or lab experiments are described that way, and observational studies, which can show a link between a drug and an outcome but not cause and effect, are kept apart from randomized controlled trials. When a source discloses who paid for a study, we report the funder, especially when the funder makes the drug being studied. We do not compare results from separate trials as if the drugs had been tested head to head, because those trials usually enrolled different people and measured outcomes in different ways. A drug that is still in clinical trials is described as investigational rather than as an available treatment.
Prices
Every price in our pricing guides links to its source and shows the date we checked it. We explain the difference between a drug's list price, which is the wholesale acquisition cost a manufacturer sets before discounts, and the amount most people pay through insurance, manufacturer savings programs, or cash-pay pharmacies. Because prices change often, each guide shows the date of its most recent update.
Updates and corrections
When new information changes an article, we update it, keep the original publication date, and show an "Updated" date alongside it. When we find an error, we fix it and add a dated note, such as "Correction (October 5, 2026)," that explains what was wrong and what we changed. If the same mistake appears in other articles or translations, we correct those pages as well, and we do not quietly remove errors.
To report a mistake, email hello@peptidenewsdigest.org with a link to the page and, if possible, a link to a source that shows the correct information.
Not medical advice
Our articles explain research, regulation, and drug prices for a general audience. They are not medical advice and cannot replace a clinician who knows your health history, so talk with a qualified health professional before you start, stop, or change any treatment.
Publisher
Peptide News Digest is published by Longevity Insights LLC. Questions about this site or our standards can go to hello@peptidenewsdigest.org. Read more about the site.